Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? The Motley Fool
Covered in this story
Analyst targets on Lilly (Eli)
- Cantor Fitzgerald: $1.19k → $1.44k by Oct 2027 · Overweight via Stocktwits
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LLY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lilly (Eli) →Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.